Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:02 07/06/2024 am IST			5-day change	1st Jan Change
104.3 ^USD	+1.01%		+2.49%	-5.27%

30/05	U.S. FDA set to reorganize its food division starting October	RE
30/05	Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115	MT

Thomas C. Freyman, Executive Vice President, Finance and Administration Plans to Retire from Abbott

December 10, 2016 at 03:21 am IST

Abbott announced that Thomas C. Freyman, Executive Vice President, Finance and Administration, informed Abbott on December 8, 2016 that he plans to retire from the company after 38 years of service, effective February 1, 2017.

Latest news about Abbott Laboratories

U.S. FDA set to reorganize its food division starting October	30/05	RE
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115	30/05	MT
Medtronic beats quarterly profit estimates on medical devices strength	23/05	RE
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating	22/05	MT
Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit	15/05	MT
Drugmaker Abbott India posts Q4 profit rise on higher sales	09/05	RE
Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing	09/05	MT
Abbott Laboratories Announces Retirement of Robert E. Funck, Jr as Executive Vice President, Finance, Effective July 1, 2024	02/05	CI
Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee	29/04	MT
Dexcom's profit beats estimates on strong glucose monitor demand	26/04	RE
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength	26/04	RE
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126	23/04	MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating	22/04	MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept	19/04	MT
Correction to Health Care Roundup Article	18/04	DJ
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating	18/04	MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating	18/04	MT
Health Care Down After Abbott Earnings -- Health Care Roundup	18/04	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	18/04	MT
S&P 500, Nasdaq dip as interest rate concerns, earnings weigh	18/04	RE
Abbott Laboratories Raises Midpoint of 2024 Guidance After First-Quarter Beat	18/04	MT
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	17/04	MT
Wall St slips as dour earnings, chip stocks weigh	17/04	RE
Sector Update: Health Care Stocks Advance Premarket Wednesday	17/04	MT
Transcript : Abbott Laboratories, Q1 2024 Earnings Call, Apr 17, 2024	17/04

Chart Abbott Laboratories

Duration

Period

More charts

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

18/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott Laboratories

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

104.3 USD

Average target price

125.4 USD

Spread / Average Target

+20.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-5.27%	18TCr
MEDTRONIC PLC	-0.05%	11TCr
BECTON, DICKINSON AND COMPANY	-1.50%	6.94TCr
DEXCOM, INC.	-7.12%	4.59TCr
CENCORA, INC.	+15.24%	4.66TCr
HOYA CORPORATION	+7.97%	4.26TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+18.56%	3.07TCr
TERUMO CORPORATION	+16.92%	2.56TCr
ZIMMER BIOMET HOLDINGS, INC.	-6.84%	2.33TCr
WEST PHARMACEUTICAL SERVICES, INC.	-10.49%	2.3TCr

Other Medical Equipment, Supplies & Distribution